重度主动脉瓣狭窄TAVR与SAVR预后比较的系统评价与荟萃分析
结果显示TAVR术后全因死亡率和房颤发生率较低,但起搏器植入率较高,5年再手术率亦较高;作者认为TAVR是优选治疗方式。
要点
- TAVR术后1年全因死亡率低于SAVR(RR=0.85,95%CI 0.74~0.97,P=0.01)。
- TAVR术后1、2、5年新发房颤率均低于SAVR(P均<0.001)。
- TAVR术后1、2、5年起搏器植入率高于SAVR,5年再手术率亦较高。
核心结论
- TAVR术后全因死亡率和房颤发生率低于SAVR,作者认为TAVR是重度主动脉瓣狭窄的优选治疗方式。
研究设计与样本
- 系统检索PubMed、EMBASE、Scopus、Cochrane Library、中国生物医学文献数据库、CNKI、万方和维普数据库2012年1月至2022年2月的随机对照试验(RCT)。
- 采用Jadad量表评价文献质量,使用RevMan 5.4.1软件进行荟萃分析。
主要发现
- 随访1个月:TAVR组新发房颤率低于SAVR组(RR=0.28,95%CI 0.21~0.38,P<0.001),全因死亡、卒中、起搏器植入与再手术率差异无统计学意义(P均>0.05)。
- 随访1年:TAVR组全因死亡率(RR=0.85,95%CI 0.74~0.97,P=0.01)及新发房颤率(RR=0.28,95%CI 0.20~0.39,P<0.001)低于SAVR组,起搏器植入率高于SAVR组(RR=1.79,95%CI 1.11~2.89,P=0.02),卒中与再手术率无显著差异(P均>0.05)。
- 随访2年:TAVR组起搏器植入率高于SAVR组(RR=2.23,95%CI 1.28~3.86,P=0.004),新发房颤率低于SAVR组(RR=0.46,95%CI 0.38~0.56,P<0.001),全因死亡、卒中及再手术率无显著差异(P均>0.05)。
临床怎么用
- 对于重度主动脉瓣狭窄患者,选择TAVR时需权衡较低的全因死亡和房颤风险与较高的起搏器植入及远期再手术风险。
- TAVR术后应关注起搏器植入风险及远期再手术可能性,SAVR术后应关注房颤发生风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To systematically review the prognosis of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis. Methods: A systematic search of PubMed, EMBASE, Scopus, Cochrane Library, China biomedical literature database, China journal full text database (CNKI), Wanfang database and VIP database from January 2012 to February 2022 was conducted for randomized controlled trial (RCT) that comparing TAVR and SAVR in the treatment of severe aortic stenosis. The primary outcomes were the incidence of all-cause mortality, stroke incidence, reoperation rate and complications (pacemaker implantation, atrial fibrillation) at 1 month and 1, 2, 5 years after operation. Jadad scale was used to evaluate the literature quality of RCTs. All statistical analyses were performed using the standard statistical procedures provided in RevMan 5.4.1. Results: A total of 17 studies including 11 712 patients were identified, including 6 007 patients treated with TAVR and 5 705 patients treated with SAVR. There were 4 high-quality studies and 13 medium-quality studies. The results of meta-analysis showed that the rate of new onset atrial fibrillation was lower in TAVR group than that in SAVR group (RR=0.28, 95%CI 0.21-0.38, P<0.001), and there was no significant difference in all-cause death, stroke, pacemaker implantation and reoperation rate (all P>0.05) at 30 days follow-up. At one year after TAVR and SAVR treatment, all-cause mortality (RR=0.85, 95%CI 0.74-0.97, P=0.01) and new onset atrial fibrillation (RR=0.28, 95%CI 0.20-0.39, P<0.001) were lower in TAVR group than SAVR group. However, the pacemaker implantation rate was higher in TAVR group than that of SAVR group (RR=1.79, 95%CI 1.11-2.89, P=0.02), while there was no significant difference in the incidence of stroke and reoperation between the two groups (P>0.05). At two years after TAVR and SAVR treatment, the pacemaker implantation rate was higher in TAVR group than that in SAVR group (RR=2.23, 95%CI 1.28-3.86, P=0.004), and the rate of new atrial fibrillation was lower in TAVR group than that in SAVR group (RR=0.46, 95%CI 0.38-0.56, P<0.001). There was no significant difference in all-cause death, stroke and reoperation rates between the two groups (P>0.05). At five years after TAVR and SAVR treatment, the pacemaker implantation rate (RR=1.89, 95%CI 1.13-3.17, P=0.02) and reoperation rate (RR=3.64, 95%CI 1.75-7.58, P=0.000 5) were higher in TAVR group than those in SAVR group, while the rate of new onset atrial fibrillation was lower in TAVR group than that in SAVR group (RR=0.45, 95%CI 0.37-0.55, P<0.001). There was no significant difference in all-cause death and stroke incidence between the two groups (all P>0.05). Conclusions: The all-cause mortality and the incidence of new onset atrial fibrillation after TAVR are lower than SAVR, and TAVR is a preferred therapy for patients with aortic stenosis. 目的: 系统评价经导管主动脉瓣置换术(TAVR)对比外科主动脉瓣置换术(SAVR)治疗主动脉瓣狭窄的预后。 方法: 检索 PubMed、Embase、Scopus、Cochrane Library、中国生物医学文献数据库、中国期刊全文数据库(CNKI)、万方数据库和维普数据库,检索发表于2012年1月至2022年2月的文献,筛选对比评估TAVR和SAVR治疗主动脉瓣狭窄的有效性和安全性的随机对照试验(RCT),结局指标包括术后1个月及1、2、5年的全因死亡率、卒中发生率、再手术率及并发症(起搏器置入、心房颤动)发生率。采用Jadad量表对纳入文献进行质量评价。运用RevMan 5.4.1软件进行统计学分析。 结果: 纳入17篇文献,共11 712例患者,其中接受TAVR治疗者6 007例,接受SAVR者5 705例。高质量研究4篇,中等质量研究13篇。荟萃分析结果显示,患者接受TAVR和SAVR治疗后随访1个月,TAVR组新发心房颤动率低于SAVR组(RR=0.28,95%CI 0.21~0.38,P<0.001),全因死亡、卒中、起搏器置入与再手术率差异均无统计学意义(P均>0.05)。TAVR和SAVR治疗后随访1年,TAVR组的全因死亡率(RR=0.85,95%CI 0.74~0.97,P=0.01)及新发心房颤动率(RR=0.28,95%CI 0.20~0.39,P<0.001)低于SAVR组;但起搏器置入率高于SAVR组(RR=1.79,95%CI 1.11~2.89,P=0.02),而两组的卒中发生率及再手术率差异均无统计学意义(P均>0.05)。TAVR和SAVR治疗后随访2年,TAVR组的起搏器置入率高于SAVR组(RR=2.23,95%CI 1.28~3.86,P=0.004),新发心房颤动率低于SAVR组(RR=0.46,95%CI 0.38~0.56,P<0.001),两组在全因死亡、卒中及再手术率方面差异均无统计学意义(P均>0.05)。TAVR和SAVR治疗后随访5年,TAVR组的起搏器置入率(RR=1.89,95%CI 1.13~3.17,P=0.02)及再手术率(RR=3.64,95%CI 1.75~7.58,P=0.000 5)均高于SAVR组,而新发心房颤动率低于SAVR组(RR=0.45,95%CI 0.37~0.55,P<0.001),两组在全因死亡及卒中发生率方面差异均无统计学意义(P均>0.05)。 结论: TAVR术后全因死亡率和新发心房颤动发生率均低于SAVR,对于主动脉瓣狭窄患者其为一种优选治疗方式。.
引用
- Fan P, Ye YZ, Ma X, et al. [Comparison on the prognosis of severe aortic stenosis patients treated with transcatheter aortic valve replacement versus surgical aortic valve replacement: a systematic review and meta-analysis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 36096710. doi:10.3760/cma.j.cn112148-20220211-00100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。